Orchestra BioMed Holdings (OBIO) Other Accumulated Expenses (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Other Accumulated Expenses for 5 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 142.36% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (up 142.36% YoY), while the FY2025 annual figure was $1.6 million, up 172.71% from the prior year.
• Other Accumulated Expenses advanced to $2.7 million in Q1 2026 per OBIO's latest filing, from $1.6 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.7 million in Q1 2026 and bottomed at $379000.0 in Q2 2024.
• Historically, Other Accumulated Expenses has averaged $1.2 million across 5 years, with a median of $1.1 million in 2023.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 61.21% — and 2025, when it jumped 172.71%.
• Orchestra BioMed Holdings' Other Accumulated Expenses stood at $1.9 million in 2022, then plunged by 43.0% to $1.1 million in 2023, then plunged by 46.34% to $579000.0 in 2024, then surged by 172.71% to $1.6 million in 2025, then jumped by 68.84% to $2.7 million in 2026.
• Business Quant data shows OBIO's Other Accumulated Expenses at $2.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.7 million in Q3 2025.